HCA Healthcare (NYSE: HCA) saw its stock slide 8.8% on Friday, closing at $432.46, even as the hospital operator reported first-quarter earnings that edged past Wall Street expectations. The decline was driven by investor concerns over softer patient volumes and early signs that shifting insurance dynamics are beginning to pressure the sector.
The Nashville-based company posted revenue of $19.109 billion for the quarter ended March 31, a 4.3% increase from the same period last year. Net income attributable to HCA reached $1.620 billion, or $7.15 per diluted share, while adjusted EBITDA rose 1.9% to $3.802 billion. Despite the profit beat, market participants focused on the underlying weakness in patient traffic and a less favorable payer mix.
Volume and Payer Mix Concerns
HCA's results highlighted a significant drop in respiratory admissions, which fell 42% year-over-year, while emergency room visits related to respiratory conditions declined 32%. The company also noted that a January winter storm negatively impacted volumes in key markets including Texas, Tennessee, North Carolina, and Virginia. Chief Financial Officer Mike Marks attributed approximately $180 million of the adjusted EBITDA shortfall to these two factors, describing them as "temporal and not structural."
Investors were also rattled by evidence that shifts in the insurance market, particularly the growing share of Affordable Care Act exchange plans and an uptick in uninsured treatments, are starting to weigh on reimbursement. HCA's same-facility admissions edged up 0.9% and equivalent admissions gained 1.3%, but the pace of growth was insufficient to offset margin concerns.
Industry-Wide Pressure
The sell-off extended to other hospital operators, with Tenet Healthcare (NYSE: THC) and Universal Health Services (NYSE: UHS) falling roughly 4% and 3.8%, respectively. HCA, as one of the largest U.S. hospital chains, is often seen as a bellwether for trends in patient volumes, labor costs, and reimbursement pressures. The latest data suggest that the sector may face headwinds from evolving payer behavior and seasonal demand patterns.
Barclays analyst Andrew Mok characterized the quarter as a "somewhat concerning start to the year," warning that risks could escalate if Affordable Care Act or commercial insurance trends deteriorate further. J.P. Morgan's Benjamin Rossi noted that HCA's decision to maintain its full-year guidance aligns with its historical pattern of not revising first-quarter forecasts, even when early volumes lag.
2026 Outlook Maintained
HCA reaffirmed its 2026 financial guidance, projecting revenue between $76.5 billion and $80.0 billion, adjusted EBITDA in the range of $15.55 billion to $16.45 billion, and earnings per share of $29.10 to $31.50. The company said Medicaid supplemental programs helped mitigate the impact of lower patient volumes. Chief Executive Sam Hazen described the current environment as "dynamic," but emphasized that the respiratory and storm-related drags were temporary.
CFO Mike Marks maintained the forecast of a $600 million to $900 million full-year impact from exchange-plan changes, though he said it is "a little early" to determine where results will fall within that range. Hazen added that Medicaid conversion trends have not yet stabilized, requiring more time to assess.
Payer behavior remains a persistent challenge. Marks highlighted high denial rates and underpayments, especially for Medicare Advantage plans, and noted that HCA is deploying additional technology and resources to limit the earnings impact. During the quarter, HCA repurchased 3.157 million shares for $1.571 billion and declared a quarterly dividend of $0.78 per share, payable on June 30 to shareholders of record as of June 16. As of March 31, the company operated 189 hospitals and approximately 2,600 ambulatory care locations.
